obesity

News

Graphic of faceless person with board in front of them reading Coming Soon on orange background

UK watchdog takes first action on oral weight drug adverts

Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.

News

New diabetes and obesity studies making waves at EASD

As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.

News

Woman holds a pill between index finger and thumb

New Lilly combo tops tirzepatide for weight loss in diabetes

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.

News

Lilly fleshes out triple G data in diabetes and obesity

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

Novo turns to Hengrui for another oral obesity drug

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

News

Roche culls myostatin candidate from obesity pipeline

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

UK watchdog takes first action on oral weight drug adverts

New diabetes and obesity studies making waves at EASD

New Lilly combo tops tirzepatide for weight loss in diabetes

Lilly fleshes out triple G data in diabetes and obesity

Novo turns to Hengrui for another oral obesity drug

Roche culls myostatin candidate from obesity pipeline

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks